<DOC>
	<DOCNO>NCT01743989</DOCNO>
	<brief_summary>This study aim assess optimal duration nilotinib 300 mg BID consolidation treatment , order patient remain treatment-free remission ( ≥MR4.0 ) 12 month start Treatment-Free Remission ( TFR ) phase study . Rationale : CP-CML patient receive 2 calendar year first-line imatinib treatment , fail achieve molecular response threshold treatment cessation ( ≥MR4.0 ) 50 % great chance switch nilotinib ; however optimal duration consolidation treatment nilotinib ensure high rate patient remain ≥MR4.0 enter TFR phase yet know . This protocol therefore aim assess potential impact long duration consolidation treatment nilotinib , i.e . 12 month versus 24 month , molecular relapse rate first 12 month treatment-free remission .</brief_summary>
	<brief_title>A Randomized Phase III Study Assess Effect Longer Duration Consolidation Treatment With Nilotinib TFR CP CML .</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Key Confirmed diagnosis chronic phase Ph+ CML Previous firstline treatment imatinib minimum 2 year ; Patient complete cytogenetic response ; Key Previous achievement MR4.0 study entry ; Previous treatment target cell inhibitor imatinib ; Patients history detectable atypical Leukemia transcript patient detectable atypical leukemia transcript screen ; Previous anticancer agent Chronic myeloid leukemia imatinib except cytoreduction ; Severe and/or uncontrolled concurrent medical disease opinion investigator could cause unacceptable safety risk compromise compliance protocol ; History active malignancy within 5 year prior study entry exception previous concomitant basal cell skin cancer previous carcinoma situ treat curatively ; Patients recover prior surgery ; Treatment investigational agent within 4 week Day 1 ; Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>